{"schema_version":"secwatch.filing_event.v1","accession":"0001682852-24-000057","form_type":"8-K","ticker":"MRNA","cik":"0001682852","company_name":"Moderna, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.219511+00:00","generated_at":"2026-05-30T03:38:17.156342+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Moderna Q3 net income $13M, revenue $1.9B; reiterates FY product sales $3-3.5B","bullets":["GAAP net income $13M ($0.03 EPS) vs net loss of $3.6B in Q3 2023; revenue $1.9B.","Net product sales $1.8B (+4% YoY); COVID-19 sales $1.8B, RSV sales $10M (below expectations).","FY 2024 product sales guidance reiterated at $3.0-3.5B; cost of sales guidance narrowed to 40-45%.","R&D lowered to $4.6-4.7B; capex raised to ~$1.2B including Norwood campus purchase ($0.4B).","Initiated Phase 3 trials for norovirus and influenza vaccines; expanded Executive Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001682852-24-000057","json":"https://secwatch.observer/filing/0001682852-24-000057.json","markdown":"https://secwatch.observer/filing/0001682852-24-000057.md","text":"https://secwatch.observer/filing/0001682852-24-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682852/000168285224000057/0001682852-24-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682852/000168285224000057/mrna-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:38:17.156342+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}